High Growth Tech Stocks To Watch In January 2025

As we enter January 2025, global markets are grappling with inflation concerns and political uncertainties, leading to a decline in U.S. equities and underperformance of small-cap stocks, as highlighted by the Russell 2000's dip into correction territory. In this volatile environment, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience through innovation and adaptability to shifting economic conditions.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
Yggdrazil Group	30.20%	87.10%	★★★★★★
Ascelia Pharma	76.15%	47.16%	★★★★★★
CD Projekt	23.18%	27.00%	★★★★★★
Waystream Holding	22.09%	113.25%	★★★★★★
AVITA Medical	33.33%	51.81%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Pharma Mar	25.43%	56.19%	★★★★★★
TG Therapeutics	30.33%	44.07%	★★★★★★
Elliptic Laboratories	70.09%	111.37%	★★★★★★
Travere Therapeutics	29.92%	61.97%	★★★★★★

Click here to see the full list of 1223 stocks from our High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Bioneer (KOSDAQ:A064550)

Simply Wall St Growth Rating: ★★★★★★

Overview: Bioneer Corporation is a biotechnology company with operations in South Korea and internationally, holding a market cap of ₩487.30 billion.

Operations: Bioneer Corporation engages in biotechnology across multiple regions, including South Korea, the Americas, Europe, Asia, and Africa. The company operates with a market capitalization of approximately ₩487.30 billion.

Bioneer, amidst a challenging fiscal year with a significant net loss of KRW 9.98 billion in Q3 2024 and an overall downturn in sales, is pivoting towards profitability with robust forecasts indicating potential annual earnings growth of 104.84%. This anticipated turnaround is underpinned by an aggressive R&D strategy, which has historically aligned well with its revenue growth projections of 26.1% per year—outpacing the Korean market's average. Recent corporate initiatives aim to deepen investor understanding and enhance corporate value, suggesting a strategic refocus that may well position Bioneer favorably within the biotech sector's competitive landscape.

• Click here and access our complete health analysis report to understand the dynamics of Bioneer.

• Assess Bioneer's past performance with our detailed historical performance reports.

Alphamab Oncology (SEHK:9966)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Alphamab Oncology is a clinical stage biopharmaceutical company focused on the research, development, manufacture, and commercialization of oncology biologics, with a market cap of HK$3.25 billion.

Operations: Alphamab Oncology generates revenue primarily from its pharmaceuticals segment, amounting to CN¥255.87 million. The company is involved in the research, development, and commercialization of oncology biologics.

Alphamab Oncology's recent approval to initiate a phase III study for JSKN003 highlights its strategic focus on addressing critical unmet needs in oncology, particularly in recurrent ovarian cancer. This move, coupled with the innovative development of JSKN033, the first high-concentration subcutaneous co-formulation of an ADC and PD-L1 inhibitor, underscores Alphamab's commitment to enhancing drug delivery and patient compliance. These advancements reflect not only a robust R&D pipeline but also Alphamab's potential to set new standards in cancer treatment efficacy and safety.

• Unlock comprehensive insights into our analysis of Alphamab Oncology stock in this health report.

• Review our historical performance report to gain insights into Alphamab Oncology's's past performance.

Plus Alpha ConsultingLtd (TSE:4071)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Plus Alpha Consulting Co., Ltd. specializes in providing marketing solutions and has a market capitalization of approximately ¥74.28 billion.

Operations: The company generates revenue primarily from HR Solutions, contributing ¥10.13 billion, and Marketing Solutions, with ¥3.78 billion.

Plus Alpha ConsultingLtd. has demonstrated a robust financial trajectory, with revenue and earnings growth outpacing industry norms at 13.9% and 18.1% respectively over the past year, significantly higher than the software industry's average of 13.1%. This performance is bolstered by strategic capital management, evidenced by their recent share repurchase program aimed at enhancing shareholder value through a buyback of up to 2,320,000 shares for ¥3 billion. The company's commitment to R&D is evident in its allocation of substantial resources towards innovation—critical in maintaining competitive advantage in the rapidly evolving tech landscape.

• Click to explore a detailed breakdown of our findings in Plus Alpha ConsultingLtd's health report.

• Evaluate Plus Alpha ConsultingLtd's historical performance by accessing our past performance report.

Taking Advantage

• Embark on your investment journey to our 1223 High Growth Tech and AI Stocks selection here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com